Parkinson's Disease Test
Parkinson's Disease
DevelopmentActive
Key Facts
About Octave Bioscience
Octave Bioscience is a private, commercial-stage diagnostics company pioneering a data-driven approach to managing multiple sclerosis. Its core innovation is the MSDA Test, a blood-based biomarker panel that provides objective, personalized insights into disease activity, aiming to inform treatment decisions and improve patient care. The company is leveraging its platform and partnerships to establish its test in clinical practice while expanding its pipeline to include assessments for MS disease progression and Parkinson's disease. With a focus on scientific validation and real-world utility, Octave is positioning itself at the intersection of neuroscience, diagnostics, and data analytics.
View full company profileTherapeutic Areas
Other Parkinson's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| NPT200-11 | Neuropore Therapies | Phase 1 |
| NUZ-001 | Neurizon Therapeutics | Preclinical |
| VXX-301 | Vaxxinity | Preclinical |
| BAN2802 | BioArctic | Phase 1 |
| CNM-Au8 | Clene | Phase 2 |
| hpSC-Derived Neural/Dopaminergic Cells | International Stem Cell | Preclinical/Early Clinical |
| SLS-004 | Seelos Therapeutics | Preclinical |
| SLS-007 | Seelos Therapeutics | Preclinical |
| Parkinson's Disease Portfolio (Platform-derived) | WD Pharmaceutical | Not Disclosed (Likely Preclinical/Early Clinical) |
| UX-DA001 | UniXell | Phase 1 |
| Parkinson's Disease Research | ProgenaBiome | Research |
| A9 Dopaminergic Neuron Therapy | Trailhead Biosystems | Pre-clinical |